Caribou Biosciences (CRBU) Receivables - Other (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Receivables - Other data on file, last reported at $1.4 million in Q1 2026.

• On a quarterly basis, Receivables - Other fell 21.64% year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $1.4 million, a 21.64% decrease from a year earlier, with the FY2025 full-year figure at $1.9 million, up 4.16% from the prior year.
• Receivables - Other for Q1 2026 stood at $1.4 million, up from $76000.0 in the prior quarter.
• Over the last five years, Receivables - Other for CRBU reached as high as $4.2 million in Q1 2022 and fell as low as -$485000.0 in Q4 2022.
• Historically, Receivables - Other has averaged $1.6 million across 5 years, with a median of $1.7 million in 2024.
• Across the five-year window, Receivables - Other sank 481.89% in 2022 and surged 345.76% in 2024, its largest moves.
• Year by year, Receivables - Other stood at -$485000.0 in 2022, then surged by 87.84% to -$59000.0 in 2023, then surged by 345.76% to $145000.0 in 2024, then tumbled by 47.59% to $76000.0 in 2025, then jumped by 1801.32% to $1.4 million in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $1.4 million in Q1 2026, $76000.0 in Q4 2025, and $1.8 million in Q3 2025.